Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Alliance Witan reports 'resilient' first-half performance

(Sharecast News) - Alliance Witan reported a "resilient" performance over the first half of 2025 on Friday, despite turbulent market conditions, maintaining its long-standing record of dividend growth and keeping its discount to net asset value steady. For the six months ended 30 June, the FTSE 100 trust said it delivered a net asset value total return of -0.7%, matching the total shareholder return.

That compared with a 0.6% rise in the MSCI ACWI index.

The company's share price declined 1.8% to 1,222.0p, while the net asset value per share also slipped 1.8% to 1,281.9p.

Its discount to net asset value remained unchanged at 4.7%, narrower than the industry and AIC Global sector averages.

The board declared a second interim dividend of 7.08p per share, bringing total dividends declared for the year so far to 14.16p - up 6.9% on the same period in 2024.

Barring unforeseen events, the company said it expected the third and fourth interim dividends to be at least equal to the first and second, setting the stage for a 59th consecutive annual dividend increase.

"It has been a hectic six months, marked by volatility and shifting investor sentiment, and I am pleased to report that the company's investment performance has remained resilient," said chair Dean Buckley.

At 1039 BST, shares in Alliance Witan were down 1.25% at 1,264p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.